21. The changes of peripheral blood cells counts and hemoglobin levels in patients with multiple myeloma
Main Article Content
Abstract
To determine the changes in the amount of peripheral blood cells and hemoglobin levels in newly diagnosed multiple myeloma patients at Military Hospital 103 in the period 2017 - 2023. Cross sectional study was conducted on 77 patients diagnosed with multiple myeloma at Military Hospital 103 from 2017 to 2023. There were statistically significant differences in hemoglobin levels between groups based on plasmatocyte percentages in bone marrow, serum creatinine levels, disease stages or types. In particular, the percentage of patients with hemoglobin levels below 100g/L in groups with plasmocytes percentage ≥ 30%, creatinine level ≥ 177 µmol/, disease stage ISS III and IgA disease type are the highest with the corresponding respectively values: 87.5%; 100%; 89.7% and 91.3%. There were differences in the amount of platelets according to the percentages of plasmocytes in the bone marrow and serum creatinine levels, with p < 0.05. The amount of white blood cells and granulocytes has statistically significant differences according to the types and stages of the disease.
Article Details
Keywords
Multiple myeloma, peripheral blood cells, Military Hospital 103
References
2. Carlisi M, Presti RL, Plano F, et al. Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma. Scientific Reports. 2024;14(1):2832.
3. Phạm Phương Thảo, Vũ Minh Phương, Dương Hải Yến. Mối liên quan giữa tỉ số của một số tế bào máu với mức lọc cầu thận ở bệnh nhân đa u tủy xương có suy thận được điều trị tại Bệnh viện Bạch Mai. Journal of 108-Clinical Medicine and Phamarcy. 2023;18(3):49-55.
4. Nguyễn Tuấn Tùng, Vương Sơn Thành. Khảo sát mối liên quan giữa tế bào và mô bệnh học tủy xương với giai đoạn bệnh ở bệnh nhân đa u tủy xương. Tạp chí Y học Việt Nam. 2023;527(2):358-364.
5. Fiala MA, Slade M, Keller J, et al. The Association of International Staging System (ISS) Stage with Disease and Symptom Burden in Patients with Newly Diagnosed Multiple Myeloma. Blood. 2015;126(23):2115.
6. Liang F, Dong X, Tang G, et al. Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma. Zhonghua xue ye xue za zhi. 2021;42(4):332-337.
7. Nguyễn Tuấn Tùng, Vũ Minh Phương, Vương Sơn Thành. Mô tả đặc điểm tế bào và mô bệnh học tủy xương ở bệnh nhân đa u tủy xương tại Bệnh viện Bạch Mai 2016 - 2022. Tạp chí Y học Việt Nam. 2023;527(2):339-343.
8. Al Saleh AS, Sidiqi MH, Dispenzieri A, et al. Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. American journal of hematology. 2020;95(1):4-9.
9. Kyle RA, Gertz MA, Witzig TE. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.
10. Sharma S, Nemeth E, Chen Y-H, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research. 2008;14(11):3262-3267.
11. Banaszkiewicz M, Małyszko J, Batko K, et al. The key role of hepcidin-25 in anemia in multiple myeloma patients with renal impairment. Medicina. 2022;58(3):417.
12. Lê Bảo Ngọc, Beaupha SMC. Hiệu quả điều trị của phác đồ bortezomib, cyclophosphamide và dexamethasone (vcd) trên bệnh nhân đa u tủy có suy giảm chức năng thận. Tạp chí Y học Việt Nam. 2021;505(2):101-105.
13. Huang H, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagulation & Fibrinolysis. 2015;26(5):555-559.
14. Sindhu ER, Das AY, Padmanabhan M, et al. Correlation of Plasma Cell Percentage and Monoclonal Gammapathies with Biochemical Parameters in Multiple Myeloma Patients: A Retrospective Study. Asian Pacific Journal of Cancer Care. 2023;8(4):685-689.